Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Apr 26, 2022
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
Apr 05, 2022
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Mar 25, 2022
Tiziana Announces Availability of March 14 KOL Event Replay
Mar 15, 2022
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
Mar 11, 2022
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
Mar 10, 2022
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
Mar 01, 2022
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
Feb 10, 2022
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
Feb 04, 2022
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference
Jan 26, 2022
Displaying 1 - 10 of 387